|Bid||5.15 x 1100|
|Ask||6.32 x 1000|
|Day's Range||5.22 - 6.00|
|52 Week Range||5.21 - 31.99|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.33|
Spesana has partnered with Biodesix Inc., a Colorado-based diagnostics solutions business that provides molecular diagnostics tests, with a focus on lung cancer.
MEMPHIS, Tenn., December 01, 2021--Spesana, the developer of a novel electronic operating system to unify EMRs, and Biodesix Inc. (NSDQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the United States utilizing Spesana’s digital platform solutions for comprehensive lung cancer management. Spesana is a cloud based Digit
Market forces rained on the parade of Biodesix, Inc. ( NASDAQ:BDSX ) shareholders today, when the analysts downgraded...